Cold sore virus linked to Alzheimer's

15 December 2008

The virus behind cold sores is a major cause of the insoluble protein plaques found in the brains of Alzheimer's disease sufferers, University of Manchester, UK, researchers have revealed. They believe the herpes simplex virus is a significant factor in developing the debilitating disease and could be treated by antiviral agents such as acyclovir, which is already used to treat cold sores and other diseases caused by the herpes virus. Another future possibility is vaccination against the virus to prevent the development of the disease in the first place.

AD is characterized by progressive memory loss and severe cognitive impairment. It affects over 20 million people worldwide, and the numbers will rise with increasing longevity. However, despite enormous investment into research on the characteristic abnormalities of the AD brain - amyloid plaques and neurofibrillary tangles - the underlying causes are unknown and current treatments are ineffective.

Ruth Itzhaki and her team at the University's Faculty of Life Sciences have investigated the role of the Herpes Simplex virus type 1 (HSV1) in AD, publishing their recent findings in the Journal of Pathology. The scientists now hope to obtain funding to take their research further.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight